Spanish SME developing gas sensor and electronic nose systems for health diagnostics, environmental monitoring, and energy applications using nanomaterials and AI.
NVISION is a Spanish technology SME specializing in gas sensor systems and electronic nose technology for health monitoring and diagnostic applications. They develop sensor-based solutions that detect volatile organic compounds and biomarkers — applying this core capability across human health monitoring (elderly care, cardiac disease detection), veterinary diagnostics (canine leishmaniasis), and energy storage systems. Their work combines nanomaterials expertise with machine learning and physiological data analysis to turn chemical signals into actionable intelligence.
Central technology in EDGE (elderly gas sensor monitoring), EarlyCare (health monitoring with gas sensors), CANLEISH (electronic nose for disease diagnosis), and rooted in GrapheneCore1 nanomaterials work.
Coordinated both EDGE (ADL monitoring of elderly) and EarlyCare (early detection of heart and micturition diseases), and contributed to CANLEISH (veterinary diagnostics).
EarlyCare explicitly lists machine learning and explainable AI for physiological data analysis; CANLEISH uses GC-MS data analysis for biomarker detection.
Participated in GrapheneCore1 (graphene-based technologies) and CANLEISH uses nanomaterial-based chemical gas sensors.
Participated in CUBER (flow batteries) and HELIOS (modular battery packs with performance and health management), likely contributing sensor and monitoring expertise.
NVISION began in 2016 working on foundational graphene and layered materials through the Graphene Flagship, building core competence in advanced nanomaterials for sensing. From 2019 onward, they pivoted decisively toward applied gas sensor systems — first for elderly monitoring (EDGE), then expanding into health diagnostics with ML integration (EarlyCare) and veterinary disease detection via electronic nose (CANLEISH). Simultaneously, they entered the energy storage space, likely contributing their sensor and monitoring expertise to battery management projects (CUBER, HELIOS).
NVISION is converging on AI-enhanced gas sensing for medical and veterinary diagnostics — expect them to pursue clinical validation and commercialization of electronic nose devices.
NVISION operates as both a project leader and a specialist contributor. They coordinate smaller, focused projects where gas sensors are the core technology (EDGE, EarlyCare), while joining larger consortia as a sensor technology provider (GrapheneCore1, HELIOS, CUBER). With 222 unique partners across 31 countries from just 6 projects, they are comfortable working in large international consortia and bring a specific technical capability rather than broad generalist support.
Extensive network of 222 unique partners across 31 countries, built largely through participation in large flagship-scale projects like GrapheneCore1 and HELIOS. Their reach is pan-European with no obvious geographic concentration beyond their Spanish base.
NVISION sits at a rare intersection: they combine nanomaterial-based gas sensor hardware with machine learning software to create diagnostic tools. Unlike pure sensor manufacturers, they understand the full chain from chemical detection to data interpretation to clinical or industrial application. Their ability to apply the same core electronic nose technology across human health, veterinary medicine, and energy storage monitoring makes them a versatile and valuable partner for any consortium needing advanced chemical sensing.
